Vivesto

Share Issue/Capital Change • Jan 2, 2026

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

Vivesto publishes information document regarding the rights issue

The Board of Directors of Vivesto AB ("Vivesto" or the "Company") has prepared and published an information document regarding the Company's new issue of shares with preferential rights for existing shareholders of approximately SEK 53.8 million, which was resolved by the Board of Directors on 20 November 2025 and approved by the Extraordinary General Meeting on 22 December 2025 (the "Rights Issue").

Information document

In connection with the Rights Issue, the Company has prepared an information document (the " Information Document") in accordance with Article 1.4 db and Article 1.5 ba of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC as amended (the "Prospectus Regulation"). The Information Document has been prepared in accordance with the requirements of Annex IX to the Prospectus Regulation.

Vivesto today announces that the Information Document has been registered with the Swedish Financial Supervisory Authority and is available on the Company's website, www.vivesto.com, and on Bergs Securities' website, www.bergssecurities.se.

The Rights Issue in brief

• Each existing share in the Company held on the record date for the Rights Issue entitles to one (1) subscription right. Each subscription right entitles to subscription for one (1) share. This entails that the Rights Issue comprises no more than 538,043,455 new shares.
• The subscription price has been set at SEK 0.10 per share, which, provided that the Rights Issue is fully subscribed, corresponds to total issue proceeds of approximately SEK 53.8 million before issue costs.
• The subscription period runs from and including 8 January up to and including 22 January 2026.
• Subscription rights not exercised during the subscription period will become invalid and lose their value. Trading in subscription rights is planned to take place on Nasdaq Stockholm from and including 8 January 2026 up to and including 19 January 2026.

• The record date for participation in the Rights Issue is 5 January 2026. The last day of trading in the Company's shares including the right to receive subscription rights was 30 December 2025. The shares will be traded without the right to receive subscription rights from and including 2 January 2026. Application for subscription for shares may also take place without exercise of subscription rights.
• The Company has received subscription commitments from existing shareholders totalling approximately SEK 14.8 million, corresponding to approximately 27.5 percent of the Rights Issue. Furthermore, Arwidsro Investment AB has provided a guarantee undertaking of SEK 15 million through a so-called top guarantee. In addition, an existing shareholder and a number of external investors have provided guarantee undertakings totalling approximately SEK 24.0 million through so-called bottom guarantees. In total, the Rights Issue is fully covered by subscription commitments and guarantee undertakings.
• The net proceeds from the Rights Issue are mainly intended to be used to complete the ongoing pilot study with Paccal Vet in dogs, the ongoing dose-determination study in cats, as well as to conduct preclinical trials with Cantrixil and a pilot study with Cantrixil in dogs. Furthermore, up to SEK 15 million is intended to be used to repay loans under the credit facilities entered into with Arwidsro in April and November 2025. In addition, the proceeds are intended to be used for general corporate purposes.
• Based on the current cost structure and development plan, Vivesto's assessment is that the proceeds from the Rights Issue will finance the operations into the second half of 2027.

Timetable for the Rights Issue

First day of trading in the share excluding the right to receive subscription rights	2 January 2026
Record date for the Rights Issue	5 January 2026
Trading in subscription rights	8 – 19 January 2026
Subscription period	8 – 22 January 2026
Trading in paid subscribed shares (BTA)	8 January 2026 – around 6 February 2026
Expected date for publication of the outcome of the Rights Issue	23 January 2026

Advisors

In connection with the Rights Issue, Vivesto has engaged Bergs Securities as financial advisor and Sole Bookrunner. TM & Partners is acting as legal advisor to the Company.

For more information:

Erik Kinnman, Chief Executive Officer, Vivesto

Phone: +46 018-50 54 40 E-mail: IR@vivesto.com

About Vivesto AB

Vivesto is a Swedish development company that aims to offer new treatment options for hard-totreat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.

Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Vivesto in any jurisdiction, neither from Vivesto nor from someone else.

This press release is not a prospectus for the purposes of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document in accordance with Annex IX of the Prospectus Regulation. Each investor is encouraged to make their own assessment of whether it is appropriate to invest in the Company.

This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement relating to the Rights Issue is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this press release or its accuracy or completeness.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public Rights Issue of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa or in any other jurisdiction where such announcement, publication or distribution of the information would not

comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Nasdaq Stockholm's rule book for issuers.

Attachments

Vivesto publishes information document regarding the rights issue